Razuprotafib
Identification
- Name
- Razuprotafib
- Accession Number
- DB16353
- Description
Razuprotafib, also known as AKB-9778, is a small-molecule inhibitor restoring Tie2 activation by inhibiting VE-PTP.1,2 In investigations against diabetes and COVID-19, razuprotafib is self-administered by patients through subcutaneous injection.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 586.7
Monoisotopic: 586.101448095 - Chemical Formula
- C26H26N4O6S3
- Synonyms
- Razuprotafib
- External IDs
- AKB-9778
- WHO 10271
Pharmacology
- Indication
- Not Available
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
Razuprotafib inhibits VE-PTP (a negative regulator of Tie2 in diseased blood vessels) by binding and inhibiting the intracellular catalytic domain of VE-PTP that inactivates Tie2.1 This in turn allows razuprotafib to restore Tie2 activation to allow for enhancement of endothelial function and stabilization of blood vessels.2 Razuprotafib is being investigated against diabetic vascular complications and acute respiratory distress syndrome (ARDS) in COVID-19.
Target Actions Organism AReceptor-type tyrosine-protein phosphatase beta inhibitorHumans - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
Chemical Identifiers
- UNII
- 0WAX4UT396
- CAS number
- 1008510-37-9
- InChI Key
- KWJDHELCGJFUHW-SFTDATJTSA-N
- InChI
- InChI=1S/C26H26N4O6S3/c1-36-26(32)29-21(15-17-6-3-2-4-7-17)24(31)27-20(22-16-38-25(28-22)23-8-5-13-37-23)14-18-9-11-19(12-10-18)30-39(33,34)35/h2-13,16,20-21,30H,14-15H2,1H3,(H,27,31)(H,29,32)(H,33,34,35)/t20-,21-/m0/s1
- IUPAC Name
- N-{4-[(2S)-2-[(2S)-2-[(methoxycarbonyl)amino]-3-phenylpropanamido]-2-[2-(thiophen-2-yl)-1,3-thiazol-4-yl]ethyl]phenyl}sulfamic acid
- SMILES
- COC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(NS(O)(=O)=O)C=C1)C1=CSC(=N1)C1=CC=CS1
References
- General References
- External Links
- ChemSpider
- 59718647
- ChEMBL
- CHEMBL3931971
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Diabetic Macular Edema (DME) 1 2 Completed Treatment Glaucoma, Primary Open Angle (POAG) / Ocular Hypertension 1 2 Completed Treatment Nonproliferative Diabetic Retinopathy 1 2 Completed Treatment Retinal Vein Occlusion 1 2 Recruiting Treatment Acute Respiratory Distress Syndrome (ARDS) / Coronavirus Disease 2019 (COVID‑19) 1 2 Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) 1 1 Completed Treatment Glaucoma, Primary Open Angle (POAG) / Ocular Hypertension 1 1 Completed Treatment Healthy Volunteers 1 1, 2 Completed Treatment Diabetic Macular Edema (DME) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00482 mg/mL ALOGPS logP 2.64 ALOGPS logP 1.65 ChemAxon logS -5.1 ALOGPS pKa (Strongest Acidic) -1.4 ChemAxon pKa (Strongest Basic) 1.22 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 6 ChemAxon Hydrogen Donor Count 4 ChemAxon Polar Surface Area 146.72 Å2 ChemAxon Rotatable Bond Count 11 ChemAxon Refractivity 157.23 m3·mol-1 ChemAxon Polarizability 58.89 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 0 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Transmembrane receptor protein tyrosine phosphatase activity
- Specific Function
- Plays an important role in blood vessel remodeling and angiogenesis. Not necessary for the initial formation of blood vessels, but is essential for their maintenance and remodeling. Can induce deph...
- Gene Name
- PTPRB
- Uniprot ID
- P23467
- Uniprot Name
- Receptor-type tyrosine-protein phosphatase beta
- Molecular Weight
- 224299.74 Da
References
- Aerpio Pharmaceuticals: Razuprotafib (AKB-9778) Diabetic Nephropathy [Link]
Drug created on December 15, 2020 15:05 / Updated on January 20, 2021 00:46